Abstract

For advanced therapy medicinal products (ATMPs) approved in the Asia-Pacific region, the main regulatory challenge often starts after approval. Regulatory convergence has improved for product registration; however, post-approval frameworks have developed more slowly and still follow approaches designed for conventional pharmaceutical products. As a result, sponsors must meet different requirements for implementing chemistry, manufacturing and control (CMC) changes across multiple markets.

This article reviews three post-approval CMC challenge areas: ongoing data commitments, comparability requirements for manufacturing process changes and variation classification. It also discusses analytical method lifecycle management and site transfers, as these activities can affect regulatory expectations and implementation timelines. The review considers International Council of Harmonisation (ICH) guidance and national regulatory frameworks from Japan, China and Southeast Asian markets. It shows how differences in regulatory interpretation can create operational challenges and increase supply chain complexity.

Among all factors that affect post-approval change implementation, change classification has the greatest impact. It determines the regulatory pathway, supporting data requirements, and reviewing timelines and the speed of market implementation. To support successful implementation, this article proposes a five-point framework. The framework focuses on change classification, submission sequencing and supply continuity planning, and is intended for practical use within the current Asia-Pacific regulatory environment.